A phase I trial evaluating the safety, tolerability, and pharmacokinetic profile of INP12 in patients with advanced solid tumors.

2024-518126-32-00 Protocol INP12-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 15 Sep 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol INP12-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 70
Countries 1
Sites 2

Patients with advanced solid tumors.

Key facts

Sponsor
Innoup Farma S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Sep 2022 → ongoing
Decision date (initial)
2024-09-25
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518126-32-00
EudraCT number
2018-003026-84

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with advanced solid tumors.

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Innoup Farma S.L.

Sponsor organisation
Innoup Farma S.L.
Address
Plaza Cein 5, Noain C Noain C
City
Noain (Valle De Elorz)
Postcode
31110
Country
Spain

Scientific contact point

Organisation
Innoup Farma S.L.
Contact name
Maite Agüeros

Public contact point

Organisation
Innoup Farma S.L.
Contact name
Maite Agüeros

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 70 2
Rest of world 0

Investigational sites

Spain

2 sites · Ongoing, recruiting
Hospital Universitario De Navarra
Oncology, Irunlarrea Kalea 3, 31008, Pamplona
Vall D Hebron Institute Of Oncology
Oncology, Calle Natzaret 115, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-09-15 2022-11-11

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-16 Spain Acceptable with conditions
2024-09-25
2024-09-25
2 SUBSTANTIAL MODIFICATION SM-1 2025-11-18 Spain Acceptable
2025-12-19
2026-02-09